A Phase 2 interventional study of larotaxel (XRP9881) and trastuzumab in Breast Neoplasms, sponsored by Sanofi. Completed at 4 sites in 4 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-04-12.
Sponsored by Sanofi · Phase 2, Interventional, and Treatment
The primary objective of the study is to assess the activity of XRP9881 in combination with trastuzumab.
The secondary objectives are safety and pharmacokinetic interaction
12,544 studies on the registry are indexed under Breast Neoplasms; 2,892 are open to participants now.
This study's enrollment of 51 is below the median of 72 across 9,303 interventional studies indexed under Breast Neoplasms.
Browse Breast Neoplasms studies →Sanofi is the lead sponsor of 1,508 studies on the registry; 90 are open to participants now.
Of its 198 completed or terminated interventional studies of FDA-regulated products, 118 (60%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
intravenous administration
intravenous administration
Response rate (best overall response under treatment)
Time frame: study period
Incidence of grade 3-4 toxicities, pharmacokinetic interaction
Time frame: study period
This study is completed, as verified in Apr 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Sanofi